Health & Fitness
Tue, June 28, 2011Mon, June 27, 2011Sat, June 25, 2011Fri, June 24, 2011Thu, June 23, 2011Wed, June 22, 2011Tue, June 21, 2011Mon, June 20, 2011Sun, June 19, 2011Fri, June 17, 2011Thu, June 16, 2011Wed, June 15, 2011Tue, June 14, 2011Mon, June 13, 2011Fri, June 10, 2011Thu, June 9, 2011Wed, June 8, 2011Tue, June 7, 2011Mon, June 6, 2011Sat, June 4, 2011Fri, June 3, 2011Thu, June 2, 2011Wed, June 1, 2011Tue, May 31, 2011Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview
Published in Health and Fitness on Thursday, June 16th 2011 at 4:06 GMT by Market Wire
PASADENA, Calif.--([ BUSINESS WIRE ])--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.D., was featured in a Medical Research, Diagnostic Substances & Life Science Tools Report published by The Wall Street Transcript. Topics covered by Dr. Anzalone include Arrowheada™s operational and clinical progress with its RNAi, obesity and regenerative medicine programs, the Companya™s paradigm shifting technologies under development, strategic growth initiatives and key catalysts for which investors and industry experts should watch for in the near-term.
Dr. Anzalonea™s interview can be accessed on the Companya™s website at: [ www.arrowheadresearch.com ].
Published on June 14, 2011, this edition of interviews by The Wall Street Transcript offers a timely review of the sector containing expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue may be obtained by calling (212) 952-7433 or via The Wall Street Transcript Online.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health.Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.
For more information please visit [ http://www.arrowheadresearch.com ]. To be added to the Companya™s email list to receive news directly, please send an email to [ ir@arrowres.com ].
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market, that our financial initiatives will succeed or that we will be able to continue to operate as a going concern. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.
